Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q4 FY24 Earnings Presentation
19 slides from Themis Medicare's earnings presentation, May 15, 2024
Slide 1: Exchange filing cover letter
TML: CS: BSE/NSE CORR: 2024-25 15th May, 2024 Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, “Exchange Plaza”, Mumbai-400001 Bandra – Kurla Complex, BSE Scrip Code: 530199 Bandra – East, Mumbai- 400 051 NSE Scrip Code: THEMISMED
Slide 2: Themis Medicare Ltd. Investor Presentation Q4 & FY24
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Investor Presentation Q4 & FY24
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 6: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “FY24 saw the Company implement various strategies in the Hospital and Trade businesses. These initiatives have already begun benefiting the Company and have already laid a strong foundation for significant
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 22.5% 104.8 20 96.7 97.8 20% 80.1 82.5 13.1% 21.7 15 11.8% 15% 9.5% 9.8% 10 10% 12.4 10.5 9.3 5 8.1 5% 0 0% Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 PAT (Rs. Cr.) / Margin
Slide 8: Consolidated Quarterly Financial Highlights – Q4 FY24
Consolidated Quarterly Financial Highlights – Q4 FY24 Particulars (Rs. Cr.) Q4 FY24 Q4 FY23 Y-o-Y (%) Q3 FY24 Net Revenue 97.82 80.10 22.11% 82.51 Cost of Material Consumed 21.65 30.32 21.13 Purchase of SIT 11.79 10.58 18.11 • Hospital Business has grown by Changes in Inventory 5.78 (13.10) (12.77)
Slide 9: Consolidated Full Year Financial Highlights – FY24
Consolidated Full Year Financial Highlights – FY24 Particulars (Rs. Cr.) FY24 FY23 Y-o-Y (%) Net Revenue 381.76 354.32 7.74% Cost of Material Consumed 84.67 96.04 Purchase of SIT 53.61 30.12 Changes in Inventory (1.57) (7.79) Employee Expenses 82.41 66.15 Other Expenses 111.13 102.36 Total Expenditu
Slide 10: Consolidated Balance Sheet as on 31st Mar'24
Consolidated Balance Sheet as on 31st Mar’24 As on 31st As on 31st As on 31st As on 31st Rs. Cr. Rs. Cr. Mar’24 Mar’23 Mar’24 Mar’23 Shareholders Funds 377.67 339.44 Non Current Assets 273.25 249.43 Share Capital 9.20 9.20 Plant, Property & Equipment 167.81 160.98 Other Equity 368.46 330.24 Capital
Slide 11: Company Overview
MEDICARE a _ ee 4 NI A. & 4 ‘N iy | rN
Slide 12: Snapshot of Company, Strategic focus, Strong Balance Sheet
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 38% to revenue Total Debt to Equity at 0.25 in FY23-24 3 State of art manufacturing facilities in India – Rs. 2,012 Cr 1 Formulations and 2 APIs (Synthetic +
Slide 13: Strong Business Model
Strong Business Model 01 Businesswise Revenue – FY23-24 Hospital Business Hospital 36% is major growth 03 API, Co. driver Mkt & Others 49% Trade 15% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Intensive Care Division New Product pipeline Businesswise Reve
Slide 14: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 15: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14.25 Total Manpower 47 15 13.64 13.69 R&D 32 (Incl. 3 PhD) 7 (Incl. 2 PhD) 8.50 Analytical Lab 15 8 Development 4.59 Groups 5 3 3.43 Product in a year with 5–8 20-24 documentation FY18-19 FY
Slide 16: Way Ahead
Way Ahead
Slide 17: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product Port
Slide 18: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 19: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Sangameshwar Iyer Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Adfactors PR Pvt Ltd Email: sangameshwar.iyer@themismedicare.com Email: amit.sharma@adfac